Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28266692 | 0.82 | MMP2 (0.49) | MMP1MMP2MMP9MMP13KDM4E | |
| SCHEMBL10822142 | 0.81 | ALDH1A1 (0.48) | MMP1MMP2MMP9MMP13KDM4E | |
| SCHEMBL5100557 | 0.80 | MAOA (0.49) | KDM4EACHEALDH1A1MEN1MAPT | |
| SCHEMBL2514264 | 0.78 | RAB9A (0.56) | MMP1MMP13KDM4EALDH1A1MEN1 | |
| SCHEMBL2839000 | 0.77 | MMP1 (0.54) | MMP1MMP2MMP9MMP13KDM4E | |
| SCHEMBL457576 | 0.77 | MMP2 (0.54) | MMP1MMP2MMP9MMP13KDM4E | |
| SCHEMBL2497828 | 0.76 | MMP1 (0.53) | MMP1MMP2MMP9MMP13KDM4E | |
| SCHEMBL13614850 | 0.76 | MMP1 (0.53) | MMP1MMP2MMP9MMP13KDM4E | |
| SCHEMBL743961 | 0.76 | MMP13 (0.57) | MMP1MMP2MMP9MMP13KDM4E | |
| SCHEMBL1244889 | 0.76 | MMP1 (0.53) | MMP1MMP2MMP9MMP13KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885337-B1 | FTO INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2025-01-15 | — | — | EP | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| CN-107922316-B | FTO inhibitors | 北京生命科学研究所 | 2022-04-08 | — | — | CN | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| EP-3885337-A1 | FTO INHIBITORS | National Institute Of Biological Sciences, Beijing (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-20210238127-A1 | FTO Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-05 | — | — | US | disclosed |
| US-20210238127-A1 | FTO Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-05 | — | — | US | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-10988440-B2 | FTO inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-04-27 | — | — | US | disclosed |
| CN-105061313-A | Androgen receptor modulating compounds | ORION CORP | 2015-11-18 | — | — | CN | disclosed |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION | 2015-07-23 | — | — | US | disclosed |
| US-8975254-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2015-03-10 | — | — | US | disclosed |
| EP-2493858-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2014-07-02 | — | — | EP | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| CN-102596910-A | Androgen receptor modulating compounds | ORION CORP | 2012-07-18 | — | — | CN | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
| CN-101541801-A | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2009-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238127-A1 | FTO Inhibitors | FTO, ALKBH3, ALKBH1 | MMP1 2169/4885MMP2 1926/4885MMP9 1261/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | MMP1 4516/4885MMP2 3388/4885MMP9 4278/4885 |
| US-10988440-B2 | FTO inhibitors | FTO, ALKBH3, ALKBH1 | MMP1 2169/4885MMP2 1926/4885MMP9 1261/4885 |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MMP1 4516/4885MMP2 3388/4885MMP9 4278/4885 |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MMP1 4516/4885MMP2 3388/4885MMP9 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.